Scarica l'app Stockscreener
41.58
0.07%
-0.03
Pre-mercato:
41.60
0.02
+0.05%
Precedente Chiudi:
$41.61
Aprire:
$41.79
Volume 24 ore:
448.28K
Relative Volume:
0.42
Capitalizzazione di mercato:
$2.53B
Reddito:
-
Utile/perdita netta:
$-103.69M
Rapporto P/E:
-22.38
EPS:
-1.8579
Flusso di cassa netto:
$-70.46M
1 W Prestazione:
-3.26%
1M Prestazione:
+7.08%
6M Prestazione:
+124.76%
1 anno Prestazione:
+103.92%
Intervallo 1D:
$40.72
$42.99
Intervallo di 1 settimana:
$40.06
$43.84
Portata 52W:
$14.79
$48.53
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Nome
Enliven Therapeutics Inc
Settore
Industria
Telefono
720-647-8519
Indirizzo
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
41.58 | 2.53B | 0 | -103.69M | -70.46M | -1.8579 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Iniziato | Goldman | Buy |
| 2024-12-13 | Iniziato | BTIG Research | Buy |
| 2024-09-09 | Iniziato | H.C. Wainwright | Buy |
| 2024-06-11 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-09 | Iniziato | Mizuho | Buy |
| 2023-03-29 | Iniziato | Jefferies | Buy |
Mostra tutto
Enliven Therapeutics Inc Borsa (ELVN) Ultime notizie
Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio - MSN
Enliven Therapeutics (ELVN) price target increased by 11.14% to 52.02 - MSN
Wall Street Zen Downgrades Enliven Therapeutics (NASDAQ:ELVN) to Sell - MarketBeat
Pictet Asset Management Holding SA Sells 94,852 Shares of Enliven Therapeutics, Inc. $ELVN - MarketBeat
Director sale notice — Enliven Therapeutics (NASDAQ: ELVN) files Form 144 - Stock Titan
[ARS] Enliven Therapeutics, Inc. SEC Filing - Stock Titan
Enliven Therapeutics (NASDAQ: ELVN) seeks larger share authorization - Stock Titan
Enliven Therapeutics (ELVN) Stock: Industry Opportunities (+0.82%) 2026-04-27Trending Social Stocks - Newser
Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Enliven Therapeutics CMO Helen Collins sells over $238k in stock By Investing.com - Investing.com South Africa
Enliven Therapeutics CMO Helen Collins sells over $238k in stock - Investing.com Australia
Enliven Therapeutics (ELVN) CMO sells 5,000 shares after option exercise - Stock Titan
Trading the Move, Not the Narrative: (ELVN) Edition - Stock Traders Daily
Enliven Therapeutics (ELVN) Stock: Risk Analysis (Slight Loss) 2026-04-20Real-time Trade Ideas - Cổng thông tin điện tử tỉnh Lào Cai
Enliven Therapeutics (ELVN) Stock Investment Grade (Smart Money Active) 2026-04-18Crowd Trend Signals - UBND thành phố Hải Phòng
Enliven Therapeutics Stock Surges 194 Percent Amid CML Market Interest - HarianBasis.co
Enliven Therapeutics stock hits 52-week high at $46.83 By Investing.com - Investing.com India
Enliven Therapeutics (ELVN) soars to 5-year high as analysts 'upbeat' - MSN
Enliven Therapeutics (NASDAQ:ELVN) Hits New 1-Year HighTime to Buy? - MarketBeat
Enliven Therapeutics stock hits 52-week high at $46.83 - Investing.com
Enliven Therapeutics (ELVN) Up 194% This Year on Strong CML Market - Insider Monkey
Enliven (ELVN) gets higher price targets from HC Wainwright and Mizuho - MSN
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Down 26.3% in March - MarketBeat
Enliven Therapeutics (NASDAQ: ELVN) asks shareholders to approve charter share increase - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4.2%What's Next? - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ELVN Earnings History & Surprises | EPS & Revenue Results | ENLIVEN THERAPEUTICS INC (NASDAQ:ELVN) - ChartMill
(ELVN) Volatility Zones as Tactical Triggers - Stock Traders Daily
ELVN Surges Amid Strategic Acquisition Talks and Analyst Upgrades - StocksToTrade
H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details - Investing.com Canada
Merck’s Acquisition Ups Competition in Pharmaceuticals, Enliven Shines - timothysykes.com
Merck’s Acquisition Sparks Surge in Enliven Therapeutics - StocksToTrade
Enliven Therapeutics Regains Attention as Stock Prices Soar - timothysykes.com
Enliven Therapeutics stock hits 52-week high at $40.66 - Investing.com
Enliven Therapeutics stock hits 52-week high at $40.66 By Investing.com - Investing.com South Africa
Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho - Insider Monkey
Enliven Therapeutics Inc Azioni (ELVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):